title: [Treatment of benign prostatic hyperplasia (BPH) by transurethral needle ablation (TUNA) and 36-month follow-up of the retreatment rate].
abstract: OBJECTIVE
  Benign prostatic hyperplasia (BPH) is a disease affecting about 25% of men over the age of 40. One half of these men report symptoms that interfere with their daily activities.
  
  
  METHODS
  In this multicentre study, 102 patients with BPH were treated by transurethral needle ablation (TUNA). The efficacy of treatment was evaluated for 12 months after the operation by means of Madsen and IPSS (International Prostate Symptom Score) scores. The course of uroflowmetry and quality of life (International Score) and sexual function were also assessed for one year. The safety of treatment was evaluated according to the type and frequency of complications. The results show an immediate and significant improvement of symptoms (p < 0.0001 for Madsen and IPSS scores and maximum flow rate between M0 and M12) demonstrating the efficacy of the TUNA system. A very positive impact of TUNA was demonstrated on quality of life. No negative impact was reported on sexual function and the operation had very few repercussions with a low adverse event rate. The retreatment rate (surgical and/or drug) was evaluated 36 months after the operation by means of an optional follow-up questionnaire subsequently completed by the investigators.
  
  
  RESULTS
  After 3 years, based on the 80 questionnaires returned, 43 patients (53.8%) were stable and did not need any other medical or surgical treatment for BPH. Thirty-seven (37) patients (46.3%) required retreatment: 21 were treated with drugs (26%), 17 were treated surgically (21.25%) including 1 patient who was also retreated with drugs. This study demonstrates the significant and lasting improvement of BPH symptoms by TUNA, which constitutes an alternative attractive to surgery in young patients and/or patients worried about their sexuality.
authors.affiliation: Service d'Urologie, Hôpital Edouard Herriot, Lyon, France. xavier.martin@chu-lyon.fr
authors.forename: Xavier
authors.initials: X
authors.lastname: Martin
authors.forename: Abbou
authors.initials: A
authors.lastname: Claude
authors.forename: Marc
authors.initials: M
authors.lastname: Colombel
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Sarramon
authors.forename: Philippe
authors.initials: P
authors.lastname: Ballanger
authors.forename: Bernard
authors.initials: B
authors.lastname: Lobel
authors.forename: François
authors.initials: F
authors.lastname: Richard
authors.forename: Christian
authors.initials: C
authors.lastname: Saussine
authors.forename: Christophe
authors.initials: C
authors.lastname: Cavillon
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Buzelin
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Baron
authors.forename: Didier
authors.initials: D
authors.lastname: Lambert
authors.forename: Olivier
authors.initials: O
authors.lastname: Haillot
mesh_terms: D017115:Catheter Ablation / Q000295:instrumentation; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009339:Needles; D011470:Prostatic Hyperplasia / Q000601:surgery*; D019233:Retreatment; D011795:Surveys and Questionnaires; D013997:Time Factors